Previous studies have shown the overexpression of MT to be a prognostic marker for tumor progression and drug resistance in, i.a., ovarian [25,29], breast [30], lung [31], renal [32], bladder [33] and oral cancer [34] and melanoma [35]. This evidence concerns the gene MCAT and melanoma.